Format

Send to

Choose Destination
Expert Rev Respir Med. 2011 Apr;5(2):153-61. doi: 10.1586/ers.11.9.

Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.

Author information

1
Department of Pharmacology, Tulane University School of Medicine, 1430 Tulane Avenue, SL83, New Orleans, LA 70112-72699, USA.

Abstract

Pulmonary arterial hypertension is a disease characterized by a sustained increase in pulmonary arterial pressure leading to right heart failure. Current treatments focus on endothelial dysfunction and an aberrant regulatory pathway for vascular tone. Unfortunately, a large proportion of patients are unresponsive to conventional vasodilator therapy. Investigations are ongoing into the effects of experimental therapies targeting the signal transduction pathway that mediates vasodilation. Here, we briefly discuss the pathophysiology of pulmonary hypertension and endothelial dysfunction, along with current treatments. We then present a focused review of recent animal studies and human trials examining the use of activators and stimulators of soluble guanylate cyclase for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

PMID:
21510726
PMCID:
PMC3108035
DOI:
10.1586/ers.11.9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center